Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4.

OBJECTIVE Previous studies have revealed the presence of IgG antifibroblast antibodies (AFAs) capable of binding to the surface of fibroblasts in systemic sclerosis (SSc) sera. Since chemokines may directly or indirectly affect the development of fibrosis, this study was undertaken to investigate the production of chemokines induced by AFAs in fibroblasts, and to characterize the signaling pathways and surface molecules involved. METHODS AFA-positive and AFA-negative IgG were tested on fibroblasts. Chemokine messenger RNA expression was screened by microarray and quantitative reverse transcription-polymerase chain reaction. Production of CCL2, CXCL8, and CXCL10 proteins was assessed by enzyme-linked immunosorbent assay. Pharmacologic inhibitors were used to study signal transduction, with results assessed by Western blotting and immunofluorescence analysis. Fibroblasts with defective expression of Toll-like receptors (TLRs) and anti-TLR monoclonal antibodies (mAb) were used to assess AFA specificity. RESULTS In human fibroblasts, AFA-positive IgG induced the preferential transcription of chemokines with profibrotic and proangiogenic potential, including, but not exclusively, CCL2, CXCL1, CXCL8, CKLF, and ECGF1, which were distinctly different from those induced by interferon-gamma. Levels of CCL2 and CXCL8 proteins were increased in AFA-stimulated fibroblast culture supernatants. AFA binding to fibroblasts resulted in concomitant activation of ERK-1/2, c-Jun, and NF-kappaB. CCL2 production was sensitive to inhibition of both proteasome and JNK, while CXCL8 production was sensitive only to inhibition of proteasome. AFAs failed to up-regulate CCL2 expression in TLR-4-deficient fibroblasts but not in TLR-6- or TLR-2-deficient fibroblasts. Moreover, anti-TLR-4 mAb, but not anti-TLR-2 mAb, partially inhibited the production of CCL2 induced by AFAs in human fibroblasts. CONCLUSION Autoantibodies that bind to the surface of fibroblasts may contribute to the pathogenesis of SSc by up-regulating the fibroblast production of profibrotic and proangiogenic chemokines, in a proteasome- and TLR-4-dependent manner.

[1]  M. Fujimoto,et al.  Immunopathology and Infectious Disease CD 19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma , 2010 .

[2]  J. Dayer,et al.  Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. , 2007, Rheumatology.

[3]  Steve Gerondakis,et al.  Coordinating TLR‐activated signaling pathways in cells of the immune system , 2007, Immunology and cell biology.

[4]  A. Marshak‐Rothstein,et al.  Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. , 2007, Annual review of immunology.

[5]  R. Strieter,et al.  The role of CXC chemokines in pulmonary fibrosis. , 2007, The Journal of clinical investigation.

[6]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[7]  E. Kruithof,et al.  The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. , 2007, Blood.

[8]  Xiaowei Liu,et al.  Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies , 2007, Annals of the rheumatic diseases.

[9]  C. Chizzolini.  Update on pathophysiology of scleroderma with special reference to immunoinflammatory events , 2007, Annals of medicine.

[10]  F. Arnett.  Is scleroderma an autoantibody mediated disease? , 2006, Current opinion in rheumatology.

[11]  M. Humbert,et al.  Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension , 2006, European Respiratory Journal.

[12]  E. Valletta,et al.  In Celiac Disease, a Subset of Autoantibodies against Transglutaminase Binds Toll-Like Receptor 4 and Induces Activation of Monocytes , 2006, PLoS medicine.

[13]  Toshiyuki Yamamoto.  Chemokines and Chemokine Receptors in Scleroderma , 2006, International Archives of Allergy and Immunology.

[14]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[15]  R. Corrocher,et al.  Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach , 2005, PLoS medicine.

[16]  D. Abraham,et al.  Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. , 2005, Arthritis and rheumatism.

[17]  J. Dayer,et al.  Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts , 2005, Arthritis research & therapy.

[18]  D. Milewicz,et al.  Autoantibodies to Fibrillin-1 Activate Normal Human Fibroblasts in Culture through the TGF-β Pathway to Recapitulate the “Scleroderma Phenotype”1 , 2005, The Journal of Immunology.

[19]  M. Burdick,et al.  CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.

[20]  M. Matthay,et al.  Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. , 2004, Blood.

[21]  F. Martinon,et al.  Identification of Bacterial Muramyl Dipeptide as Activator of the NALP3/Cryopyrin Inflammasome , 2004, Current Biology.

[22]  M. Tremblay,et al.  Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. , 2004, Arthritis and rheumatism.

[23]  William C. Parks,et al.  Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.

[24]  G. Zeng,et al.  Chemokine-like factor 1, a novel cytokine, contributes to airway damage, remodeling and pulmonary fibrosis. , 2004, Chinese medical journal.

[25]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[26]  Hideo Sakamoto,et al.  Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. , 2004, American journal of respiratory cell and molecular biology.

[27]  Shinichi Sato,et al.  Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. , 2004, Journal of dermatological science.

[28]  Stefan Bauer,et al.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. , 2004, The Journal of clinical investigation.

[29]  S. Kunkel,et al.  CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. , 2003, Cytokine.

[30]  T. Wynn,et al.  Global Gene Expression Profiles During Acute Pathogen-Induced Pulmonary Inflammation Reveal Divergent Roles for Th1 and Th2 Responses in Tissue Repair1 , 2003, The Journal of Immunology.

[31]  M. Fujimoto,et al.  Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. , 2003, The Journal of rheumatology.

[32]  A. Mantovani,et al.  Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. , 2003, Blood.

[33]  A. Gabrielli,et al.  Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. , 2002, Arthritis and rheumatism.

[34]  R. Wise,et al.  Gene expression in bronchoalveolar lavage cells from scleroderma patients. , 2002, American journal of respiratory cell and molecular biology.

[35]  M. Burdick,et al.  ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. , 2001, American journal of respiratory and critical care medicine.

[36]  M. Landthaler,et al.  Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. , 2001, Arthritis and rheumatism.

[37]  T. Yamamoto,et al.  High expression and autoinduction of monocyte chemoattractant protein‐1 in scleroderma fibroblasts , 2001, European journal of immunology.

[38]  J. Alcamí,et al.  Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. , 2001, Arthritis and rheumatism.

[39]  G. Damonte,et al.  Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells , 2000, Nature Medicine.

[40]  M. Burdick,et al.  IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. , 1999, Journal of immunology.

[41]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[42]  M. Burdick,et al.  Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. , 1999, Journal of immunology.

[43]  N. Marx,et al.  Effect of proteasome inhibitors on monocytic IκB‐α and ‐β depletion, NF‐κB activation, and cytokine production , 1998, Journal of leukocyte biology.

[44]  H. Ihn,et al.  Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. , 1998, The Journal of rheumatology.

[45]  Matthias Mann,et al.  IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .

[46]  R. Whyte,et al.  The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. , 1997, Journal of immunology.

[47]  S. Jimenez,et al.  Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. , 1993, Archives of dermatology.

[48]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[49]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[50]  R. Strieter,et al.  In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.